Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nimotuzumab: beyond the EGFR signaling cascade inhibition.
Mazorra Z, Chao L, Lavastida A, Sanchez B, Ramos M, Iznaga N, Crombet T. Mazorra Z, et al. Among authors: crombet t. Semin Oncol. 2018 Jan;45(1-2):18-26. doi: 10.1053/j.seminoncol.2018.04.008. Epub 2018 May 2. Semin Oncol. 2018. PMID: 30318080 Free article. Review.
Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.
Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernández E, Alvárez D, Torres O, Ramos M, Leonard I, Pérez R, Lage A. Crombet T, et al. J Clin Oncol. 2004 May 1;22(9):1646-54. doi: 10.1200/JCO.2004.03.089. J Clin Oncol. 2004. PMID: 15117987 Clinical Trial.
Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin.
Torres LA, Perera A, Batista JF, Hernández A, Crombet T, Ramos M, Neninger E, Pérez M, Sánchez EL, Romero S, Aguilar V, Coca MA, Iznaga-Escobar N. Torres LA, et al. Among authors: crombet t. Nucl Med Commun. 2005 Dec;26(12):1049-57. doi: 10.1097/00006231-200512000-00002. Nucl Med Commun. 2005. PMID: 16264350 Clinical Trial.
Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti- epidermal growth factor receptor monoclonal antibody Nimotuzumab.
Arteaga ME, Ledón N, Casacó A, Pardo B, García M, Boleda M, Viña L, Orphee R, Hernández O, González C, Fuentes D, Rodríguez V, Charro L, Baro F, Macías A, Pérez A, Morales Y, Subirós N, González B, Ramos M, Rodriquez L, Ballester-Labrada A, Crombet T. Arteaga ME, et al. Among authors: crombet t. Cancer Biol Ther. 2007 Sep;6(9):1390-5. doi: 10.4161/cbt.6.9.4539. Epub 2007 Jun 5. Cancer Biol Ther. 2007. PMID: 17827980
Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.
García B, Neninger E, de la Torre A, Leonard I, Martínez R, Viada C, González G, Mazorra Z, Lage A, Crombet T. García B, et al. Among authors: crombet t. Clin Cancer Res. 2008 Feb 1;14(3):840-6. doi: 10.1158/1078-0432.CCR-07-1050. Clin Cancer Res. 2008. PMID: 18245547 Clinical Trial.
58 results